42925-15-5

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 14 carbon (C) atoms, 19 hydrogen (H) atoms, 1 nitrogen (N) atom, and 1 oxygen (O) atom.
2. Bicyclic compound

Explanation

A bicyclic compound is a type of organic molecule that contains two rings of carbon atoms. In this case, the compound has two fused six-membered rings.
3. Nitrogen atom

Explanation

The compound contains a nitrogen atom, which is an essential component for various chemical reactions and properties.
4. Hydroxyl group

Explanation

The hydroxyl group (-OH) is a functional group consisting of an oxygen atom bonded to a hydrogen atom. It is present in 1-Azabicyclo[2.2.2]octan-3-ol, 3-phenyl-, contributing to its reactivity and properties.
5. Phenyl group

Explanation

A phenyl group is a functional group consisting of a six-membered carbon ring with alternating single and double bonds (also known as a benzene ring). In 1-Azabicyclo[2.2.2]octan-3-ol, 3-phenyl-, a phenyl group is attached to the third carbon of the bicyclic ring.
6. Pharmaceutical research

Explanation

The compound is used in pharmaceutical research, which involves studying its properties, reactivity, and potential applications in the development of new drugs.
7. Potential applications in drug development

Explanation

Due to its unique structure and properties, 1-Azabicyclo[2.2.2]octan-3-ol, 3-phenylmay have potential applications in the development of new drugs, particularly in the pharmaceutical industry.
8. Safety measures

Explanation

As with any chemical compound, it is important to handle 1-Azabicyclo[2.2.2]octan-3-ol, 3-phenylwith care and follow proper safety measures during its handling and use. This may include wearing protective gear, working in a well-ventilated area, and following specific guidelines for storage and disposal.
9. Potential hazards

Explanation

The compound may have potential hazards associated with its use, such as toxicity, flammability, or reactivity with other substances. It is crucial to be aware of these hazards and take appropriate precautions to minimize risks during its handling and use.

Upstream product

• 3731-38-2 3-Quinuclidinone 
• 591-51-5 phenyllithium 
• 108-86-1 bromobenzene 
• 1193-65-3 3-quinuclidinone hydrochloride 

Downstream Products

• 21628-28-4 3-phenyl-1-aza-bicyclo[2.2.2]oct-2-ene 
• 100795-12-8 2-nitro-3-phenyl-1-aza-bicyclo[2.2.2]oct-2-ene 
• 105402-28-6 2-nitro-3-(4-nitro-phenyl)-1-aza-bicyclo[2.2.2]oct-2-ene 

Relevant academic research and scientific papers

Hydroalkylation of Unactivated Olefins via Visible-Light-Driven Dual Hydrogen Atom Transfer Catalysis

Radical hydroalkylation of olefins enabled by hydrogen atom transfer (HAT) catalysis represents a straightforward means to access C(sp3)-rich molecules from abundant feedstock chemicals without the need for prefunctionalization. While Giese-type hydroalkylation of activated olefins initiated by HAT of hydridic carbon-hydrogen bonds is well-precedented, hydroalkylation of unactivated olefins in a similar fashion remains elusive, primarily owing to a lack of general methods to overcome the inherent polarity-mismatch in this scenario. Here, we report the use of visible-light-driven dual HAT catalysis to achieve this goal, where catalytic amounts of an amine-borane and an in situ generated thiol were utilized as the hydrogen atom abstractor and donor, respectively. The reaction is completely atom-economical and exhibits a broad scope. Experimental and computational studies support the proposed mechanism and suggest that hydrogen-bonding between the amine-borane and substrates is beneficial to improving the reaction efficiency.

Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors

Quinuclidines with a 3-biaryl substituent are a new class of potent, orally active squalene synthase (SQS) inhibitors. Variants around these rigid structures indicate key structural requirements for cationic SQS inhibitors. Thus the lower in vitro potency found for quinuclidines bearing 3- substituents, which did not overlay the biphenyl group of 3-(biphenyl-4-yl)- 3-hydroxyquinuclidine (2) (IC50 = 16 nM, rat microsomal SQS), implied a directional requirement for the 3-substituent. Similarly, the lower potency of the 3-terphenyl analogue 6 (IC50 = 370 nM) indicated size constraints for this substituent. In compounds with a linking group between the quinuclidine and biphenyl ring, linking groups of lower lipophilicity were less well tolerated (e.g., 17, CH2CH2, IC50 = 5 nM vs 19, NHCO, IC50 = 1.2 μM). Replacement of the distal phenyl ring of 2 with a more polar pyridine heterocycle caused a reduction in in vitro potency. In general, good in vivo activity in the rat was restricted to 3-hydroxy analogues, with the 3-[4-(pyrid-4-yl)phenyl] derivative 39 (IC50 = 161 nM) showing the best inhibition (following oral dosing) of cholesterol biosynthesis from mevalonate (ED50 = 2.7 mg/kg).